| 1 |
Interaction of Cardiovascular Nonmodifiable Risk Factors, Comorbidities and Comedications With Ischemia/Reperfusion Injury and Cardioprotection by Pharmacological Treatments and Ischemic Conditioning |
|
| | Péter Ferdinandy, Ioanna Andreadou, Gary F. Baxter, Hans Erik Bøtker, Sean M. Davidson, Dobromir Dobrev, Bernard J. Gersh, Gerd Heusch, Sandrine Lecour, Marisol Ruiz-Meana, Coert J. Zuurbier, Derek J. Hausenloy, Rainer Schulz, Finn Olav Levy | | | Pharmacological Reviews. 2023; 75(1): 159 | | | [Pubmed] [Google Scholar] [DOI] | | | 2 |
Rethinking pioglitazone as a cardioprotective agent: a new perspective on an overlooked drug |
|
| | Lorenzo Nesti, Domenico Tricò, Alessandro Mengozzi, Andrea Natali | | | Cardiovascular Diabetology. 2021; 20(1) | | | [Pubmed] [Google Scholar] [DOI] | | | 3 |
Pretreatment of ghrelin protects H9c2 cells against hypoxia/reoxygenation-induced cell death via PI3K/AKT and AMPK pathways |
|
| | Yanbo Chen, Honggang Wang, Yong Zhang, Zhengping Wang, Shanshan Liu, Lianqun Cui | | | Artificial Cells, Nanomedicine, and Biotechnology. 2019; 47(1): 2179 | | | [Pubmed] [Google Scholar] [DOI] | |
|
